BioNTech SE (LON:0A3M)

BioNTech SE Statistics

Total Valuation

BioNTech SE has a market cap or net worth of GBP 20.12 billion. The enterprise value is 7.83 billion.

Market Cap	20.12B
Enterprise Value	7.83B

Important Dates

The next estimated earnings date is Tuesday, March 10, 2026.

Earnings Date	Mar 10, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.40%
Shares Change (QoQ)	-1.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	104.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.31
PB Ratio	1.25
P/TBV Ratio	1.38
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-15.70
EV / Sales	2.89
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-18.12

Financial Position

The company has a current ratio of 7.12, with a Debt / Equity ratio of 0.01.

Current Ratio	7.12
Quick Ratio	6.89
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.50
Interest Coverage	-54.07

Financial Efficiency

Return on equity (ROE) is -3.04% and return on invested capital (ROIC) is -18.04%.

Return on Equity (ROE)	-3.04%
Return on Assets (ROA)	-2.30%
Return on Invested Capital (ROIC)	-18.04%
Return on Capital Employed (ROCE)	-4.21%
Weighted Average Cost of Capital (WACC)	12.50%
Revenue Per Employee	406,334
Profits Per Employee	-73,675
Employee Count	6,772
Asset Turnover	0.14
Inventory Turnover	2.09

Taxes

In the past 12 months, BioNTech SE has paid 43.12 million in taxes.

Income Tax	43.12M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -6.28% in the last 52 weeks. The beta is 1.51, so BioNTech SE's price volatility has been higher than the market average.

Beta (5Y)	1.51
52-Week Price Change	-6.28%
50-Day Moving Average	102.59
200-Day Moving Average	104.19
Relative Strength Index (RSI)	52.02
Average Volume (20 Days)	21,275

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.24

Income Statement

In the last 12 months, BioNTech SE had revenue of GBP 2.75 billion and -498.93 million in losses. Loss per share was -2.08.

Revenue	2.75B
Gross Profit	2.27B
Operating Income	-703.18M
Pretax Income	-455.81M
Net Income	-498.93M
EBITDA	-408.32M
EBIT	-703.18M
Loss Per Share	-2.08

Balance Sheet

The company has 12.68 billion in cash and 214.20 million in debt, with a net cash position of 12.47 billion.

Cash & Cash Equivalents	12.68B
Total Debt	214.20M
Net Cash	12.47B
Net Cash Per Share	n/a
Equity (Book Value)	16.13B
Book Value Per Share	67.07
Working Capital	11.88B

Cash Flow

In the last 12 months, operating cash flow was -276.52 million and capital expenditures -155.81 million, giving a free cash flow of -432.33 million.

Operating Cash Flow	-276.52M
Capital Expenditures	-155.81M
Free Cash Flow	-432.33M
FCF Per Share	n/a

Margins

Gross margin is 82.49%, with operating and profit margins of -25.55% and -18.13%.

Gross Margin	82.49%
Operating Margin	-25.55%
Pretax Margin	-16.56%
Profit Margin	-18.13%
EBITDA Margin	-14.84%
EBIT Margin	-25.55%
FCF Margin	n/a

Dividends & Yields

BioNTech SE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.40%
Shareholder Yield	0.40%
Earnings Yield	-2.48%
FCF Yield	-2.15%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BioNTech SE has an Altman Z-Score of 6.95 and a Piotroski F-Score of 2.

Altman Z-Score	6.95
Piotroski F-Score	2